CoChat

Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes

Open access

Published version of a preprint

The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Type 1 diabetes mellitus (T1DM) is a rare, irreversible immune-related adverse event reported in patients receiving treatment with immune checkpoint inhibitors (ICI). However, clinical risk factors for ICI-induced T1DM (ICI-T1DM) and its impact on survival in patients remain unknown. RESEARCH DESIGN AND METHODS: We used Optum's Clinformatics Data Mart database for assessment of the incidence and characteristics of T1DM in a large de-identified cohort of patients treated with ICI between 2017 and 2020. We applied Fine-Gray and cause-specific hazard models to study associations between patient/treatment characteristics and ICI-T1DM and applied the Cox model with ICI-T1DM as a time-varying covariate to assess the impact of ICI-T1DM on survival. RESULTS: ICI-T1DM was observed in 261 of 30,337 (0.86%) patients. Dual use of antibodies to cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) was associated with increasing risk of ICI-T1DM (hazard ratio [HR] 1.62; 95% CI 1.15-2.26) vs. anti-PD-L1 or anti-PD-1 alone. Younger age (HR 1.19 for every 5-year decrease; 95% CI 1.13-1.25) and preexisting non-T1DM diabetes (HR 4.48; 95% CI 3.45-5.83) were also associated with higher risk of ICI-T1DM. Conversely, prior use of immunosuppressive medications (HR 0.57; 95% CI 0.34-0.95) was associated with lower incidence of ICI-T1DM, but part of its protective effect may be due to the increased mortality rate. Development of ICI-T1DM does not seem to significantly impact patient survival. CONCLUSIONS: The risk of ICI-T1DM is associated with the type of ICI therapy, patient age, and preexisting non-T1DM diabetes. These data may help guide risk assessment and screening practices for patients during ICI therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc21-2213

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. 19. Nicolaides NC, Pavlaki AN, Alexandra MAM, et al. Glucocorticoid therapy and adrenal suppression. In Endoxtext. Feingold KR, Anawalt B, Boyce A, et al., Eds. South Dartmouth, MA, MDText.com, Inc., 2015

Cited by

See all 99

Metadata

Authors
Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., & Zhao, L.
Affiliations
  • University of Michigan (US)
  • Biostatistics and Biomathematics Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Ann Arbor, MI
  • Department of Anesthesiology, University of Michigan, Ann Arbor, MI
Corresponding author
Zhao, Lili
Venue
Diabetes Care
Published
2022-03-03
Volume
45
Issue
5
Pages
1170-1176
ISSN
0149-5992 (ISSN-L)
OpenAlex
W4214883428
Cited by
93
References
33
Citations by year
2026: 20 · 2025: 24 · 2024: 26 · 2023: 17 · 2022: 6
FWCI
7.62
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (P30CA046592)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK020572)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
immune checkpoint inhibitors, type 1 diabetes, immune-related adverse events, CTLA-4, PD-1, PD-L1, pregestational diabetes, immunosuppressants, risk factors, survival, cancer immunotherapy
MeSH terms
Immune Checkpoint Inhibitors, Diabetes Mellitus, Type 1, Humans, Retrospective Studies, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. https://app.cochat.ai/papers/10.2337/dc21-2213
The paper
Chen, X., Affinati, A. H., Lee, Y., Turcu, A. F., Henry, N. L., Schiopu, E., Qin, A., Othus, M., Clauw, D., Ramnath, N., & Zhao, L. (2022). Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc21-2213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.